Amgen's Cancer Breakthrough Could Fuel Further Gains

Nov 2, 2026

Bobby Quant Team

💡 Key Takeaway

Amgen's Imdelltra, combined with AstraZeneca's Imfinzi, reduced the risk of death by 58% in extensive-stage small cell lung cancer, a potential game-changer that could drive significant growth for the stock.

Amgen's Imdelltra Shows Promising Results in Lung Cancer Trial

Amgen (AMGN) announced that its cancer drug Imdelltra, when combined with AstraZeneca's Imfinzi, significantly reduced the risk of death in patients with extensive-stage small cell lung cancer (ES-SCLC). The combination therapy cut the risk of death by 58% compared to Imfinzi alone, with median survival extending to 21.1 months versus 12.7 months.

Small cell lung cancer is an aggressive disease often diagnosed at late stages, making these results particularly meaningful. Amgen's chief medical officer, Dr. Paul Burton, believes this combination could 'transform the standard of care' for these patients.

Imdelltra has already been a strong performer for Amgen, generating $288 million in the first half of 2026, a 115% increase year-over-year. The new data opens up an even larger opportunity in first-line treatment, potentially expanding the drug's addressable market.

Amgen's stock has risen over 40% this year, yet it still trades at a forward P/E of 19, in line with the S&P 500 average. The company has 22 products growing at double-digit rates and 17 with annual run rates exceeding $1 billion, indicating broad-based strength beyond Imdelltra.

What This Means for Me

If you hold AMGN, the positive trial data reinforces the growth story and could lead to further gains, so consider holding or adding on dips. Investors with exposure to AstraZeneca (AZN) may also benefit from the combination's success. Those holding Moderna (MRNA) should note that Amgen's established scale and diversified pipeline offer a different risk profile, but competition in oncology could impact sentiment across the sector.

Why This Data Could Be a Catalyst for Amgen Stock

The positive trial results for Imdelltra in combination with Imfinzi could significantly boost Amgen's oncology franchise. ES-SCLC is a difficult-to-treat cancer with limited treatment options, and a 58% reduction in risk of death is a substantial improvement that could lead to regulatory approval and broad adoption.

For Amgen, this represents a major growth opportunity. Imdelltra is already growing rapidly, and success in first-line ES-SCLC could propel it to blockbuster status. The combination approach also validates Amgen's pipeline and partnership strategy.

Beyond Imdelltra, Amgen's diverse portfolio and pipeline provide multiple shots on goal. With 22 products growing double digits and a reasonable valuation, the stock offers a compelling mix of growth and value. The recent run-up may not fully reflect the potential of the pipeline, especially if Imdelltra becomes a standard of care.

Investors should note that clinical trial success does not guarantee regulatory approval, and competition in oncology is intense. However, the data is strong and positions Amgen for continued momentum.

Stock to Watch

Stocks	Impact	Analysis
AMGN	Positive	Positive clinical trial results for Imdelltra, strong revenue growth, reasonable valuation, and pipeline potential suggest continued upside.
MRNA	Neutral	Mentioned as a hyped cancer vaccine play, but Amgen is positioned as a larger, safer alternative; Moderna's prospects are independent.

Source: The Motley Fool
Analysis generated by Bobby AI quantitative model, reviewed and edited by our research team. This is not financial advice. Always do your own research before making investment decisions.